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OBJECTIVE: The aim of the present study was to assess the effects of rosuvastatin on renal injury and inflammation
in a model of nitric oxide deficiency.
METHODS: Male Wistar rats were randomly divided into four groups (n=10/group) and treated for 28 days with
saline (CTRL); 30 mg/kg/day L-NAME (L-name); L-NAME and 20 mg/kg/day rosuvastatin (L-name+ROS-20); or L-NAME
and 2 mg/kg/day rosuvastatin (L-name+ROS-2). Systolic blood pressure was measured by plethysmography in the
central artery of the tail. The serum total cholesterol, triglycerides, alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase, creatinine, nitric oxide, interleukin-6, and tumor necrosis factor alpha
levels were analyzed. Urine samples were taken to measure the albumin5urinary creatinine ratio. Kidneys were
sectioned and stained with hematoxylin/eosin and Masson’s trichrome. Immunohistochemical analysis of the renal
tissue was performed to detect macrophage infiltration of the glomeruli.
RESULTS: The systolic blood pressure was elevated in the L-name but not the L-name+rosuvastatin-20 and
L-name+rosuvastatin-2 groups. The L-name group had a significantly reduced nitric oxide level and an increased
interleukin-6 and tumor necrosis factor alpha level, albumin5urinary creatinine ratio and number of macrophages in
the renal glomeruli. Rosuvastatin increased the nitric oxide level in the L-name+rosuvastatin-2 group and reduced
the interleukin-6 and tumor necrosis factor alpha levels, glomerular macrophage number and albumin5urinary
creatinine ratio in the L-name+rosuvastatin-20 and L-name+rosuvastatin-2 groups.
CONCLUSION: Rosuvastatin treatment reduced glomerular damage due to improvement in the inflammatory
pattern independent of the systolic blood pressure and serum lipid level. These effects may lead to improvements in
the treatment of kidney disease.
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INTRODUCTION
Statins, which are 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors, are currently the most popular drugs
for the management of dyslipidemia for the primary and
secondary prevention of cardiovascular disease.
1 Their
widespread use is driven by a robust body of evidence that
supports their efficacy in preventing cardiovascular events.
2
Their benefits are derived both from reducing atherogenic
lipoprotein levels (LDL-C) and from increasing antiathero-
genic lipoproteins levels (HDL-C).
3
In addition to modulating lipid levels, recent clinical and
experimental studies have shown that statins have
pleiotropic effects, including antiinflammatory, antiproli-
ferative, and antithrombotic effects; attenuation of NADPH
oxidase–mediated superoxide generation; and improvement
of endothelial vasomotor function. All of these effects may
influence cardiovascular outcomes, including hypertension,
in high-risk patients.
4 Statins reduce vascular inflammation,
suppress extracellular matrix production, exhibit inhibitory
effects on the Rho/Rho kinase pathway,
5,6 and block small
G protein isoprenylation, which is a pivotal step in the
activation of Rho.
The kidney is a target organ of hypertension. Renal
disease secondary to hypertension progressively develops,
culminating in chronic renal failure with a loss of glomeruli
and several morphological and quantitative alterations.
7,8
The renal lesions caused by nitric oxide (NO) blockade are
glomerulosclerosis, interstitial fibrosis, and microvascular
lesions.
9,10
The current chronic nephropathy treatments are limited to
angiotensin-converting enzyme inhibitors and angiotensin
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1457receptor blockers.
11 However, similar to observations in the
cardiovascular system, increasing clinical
12 and experimen-
tal
13-17 evidence indicates that statins have beneficial effects
in the course of progressive renal disease. In addition, statins
influence intrarenal hemodynamics by reducing angiotensin
and aldosterone levels.
18
Recent studies have shown that chronic administration of
L-arginine analogues such as L-nitro-arginine methyl ester
(L-NAME) to rats induces dose-dependent systemic arterial
hypertension by blocking endothelial nitric oxide synthase
(eNOS) and, therefore, NO biosynthesis.
19,20
The rat hypertension model induced by chronic inhibition
of NO generation has been shown to be a useful tool for
studying both the development and treatment of renal
lesions resembling those found in human hypertension, a
disease associated with early generalized impairment of
endothelial function.
21 This hypertension and renal disease
model seems to be a suitable model to examine the lipid
lowering–independent effects of statins because the admin-
istration of statins, even at high doses, does not alter serum
cholesterol levels in normal rats.
22-23
The aim of this study was to assess the effects of
rosuvastatin on renal injury and inflammation in a model
of nitric oxide deficiency.
METHODS AND MATERIAL
Animals
All animals (n=40; 6-week-old male Wistar rats) were
maintained in standard cages at room temperature
(22¡3˚C) and 60–70% humidity with a 12 h dark/12 h light
cycle and ad libitum food (Nuvilab, Parana ´, Brazil) and
water. This diet contained 22.5% crude protein and 0.27%
sodium. Twelve hours before each experiment, the animals
received only water to avoid interference with absorption of
the treatments. The rats were euthanized with 50 mg/kg i.p.
sodium pentobarbital. Systolic blood pressure was mea-
sured weekly in conscious rats using noninvasive tail-cuff
plethysmography (Letica 5001, Panlab, Spain) at baseline
and at the end of each week of treatment. The experiment
was conducted for four weeks. This study was conducted in
accordance with guidelines set forth by the Brazilian
Association for Laboratory Animal Science (COBEA) and
has been approved by the Research Commission for Ethics
and Animal Experimentation of UFJF.
Treatments
The rats were randomly divided into four groups (n=10/
group)andtreatedasfollows:acontrolgroup(CTRL);30 mg/
Kg/day L-NAME hydrochloride (Sigma, St. Louis, USA)
diluted in the drinking water (L-name); L-NAME+20 mg/kg/
day rosuvastatin (Crestor, AstraZeneca, Brazil) delivered by
gavage (L-name+ROS-20); and L-NAME+2 mg/kg/day rosu-
vastatin (L-name+ROS-2) delivered by gavage. The L-NAME
in the drinking water was at a concentration of 500 mg/l, and
each non-control rat received 30 mg/kg/day of L-NAME
for 28 days.
Biochemical parameters
Blood samples were drawn by cardiac puncture from the
right ventricle to measure the serum levels of total cholesterol
(TC), triglycerides (Tg), aspartate aminotransferase (AST),
alanine aminotransferase (ALT), alkaline phosphatase (ALP),
and creatinine (Cr) (Cobas Mira, Roche). The serum level of
NO was assessed using the Griess method.
24 The levels of
interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a)
were measured using enzyme-linked immunosorbent assay
(ELISA) (Opt, BD, USA) according to the manufacturer’s
instructions. Urine was obtained by bladder puncture to
establish the urine albumin: creatinine ratio (Biotecnica kit,
Cobas Mira, Roche). Analyses were performed in duplicate,
and samples were stored at -80˚C until analysis.
Histological analysis
After euthanasia, a fixative solution (1.27 mol/l of freshly
prepared formaldehyde in 0.1 M phosphate buffer; pH 7.4)
was perfused through the vascular system using a catheter
placed into the left ventricle until the body was rigid. The
kidneys were removed, cut into two halves, placed in 10%
formaldehyde for 48 h at room temperature, dehydrated,
and embedded in paraffin for histological analysis. Sections
(3 mm thick) were cut and stained with hematoxylin/eosin
for morphological analysis or Masson’s trichrome to high-
light collagen fibers. Histological analysis was performed
using a light microscope (Olympus BX51). Images were
captured (Color Coolsnap-Pro, Media Cybernetics) and
analyzed using Image Pro-Plus software (Version 6.0,
Media Cybernetics, Silver Spring, USA). The sections were
evaluated by a pathologist without prior knowledge of the
groups to which the animals belonged. Tubules (to study
tubular dilation), blood vessels (to identify intimal fibrosis,
microthrombosis and fibrinoid necrosis), glomeruli (to
identify glomerulosclerosis and glomerular atrophy), and
the interstitial compartment (to detect changes in collagen
and inflammatory cells (4006)) were analyzed morphologi-
cally to identify the range of changes. The glomerular
surface area (mm
2) was morphometrically analyzed in at
least 50 glomeruli per animal.
25
Figure 1 - Systolic blood pressure over the entire experimental
period in control and treated rats. The data are expressed as the
mean ¡ SEM for =10 rats/group. After the first week, all of the
treated groups (L-name, L-name+ROS-20, L-name+ROS-2) had
significantly increased systolic blood pressures when compared
with the CTRL group (p,0.0001).
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Immunohistochemical analysis of renal tissues to detect
the number of macrophages in 100 random glomeruli per
animal was performed on paraffin-embedded sections as
described by Hartner et al.
26 using antibodies against
macrophages/monocytes (Mouse anti-rat CD68; Serotec).
The percentage of glomeruli with macrophages was
determined by counting 100 random clusters from nearly
20 microscopic fields, in accordance with Pomaro et al.,
27
and was determined by a pathologist without prior knowl-
edge of the groups to which the animals belonged.
Statistical analysis
T h er e s u l t sa r ep r e s e n t e da st h em e a n¡ standard error
( S E M ) .T h ed a t aw e r ea l ln o r m a l l yd i s t r i b u t e di ne a c hg r o u p
(Kolmogorov-Smirnov test, p.0.05). Statistical analysis
between groups was performed using an analysis of variance
(one-way ANOVA) followed by Tukey’s test when the data
were homoscedastic. If the data were heteroscedastic, the
nonparametric Kruskal-Wallis test followed by the Tamhane
test was performed. A p-value less than 0.05 was considered
significant.Analyses wereconducted and graphswere created
using GraphPad Prism Version 5.01 for Windows (GraphPad
Software, San Diego, CA, USA) and Statistical Package for
Social Sciences Version 13.0 (SPSS, Chicago, IL, USA).
RESULTS
Systolic blood pressure analysis
The initial systolic blood pressure (SBP) was similar
among the groups. At the end of the first week of treatment
with L-NAME, all L-NAME-treated groups had an elevated
SBP compared with the control group (p,0.0001 for
all of the groups). This hypertension was observed for
all L-NAME-treated groups throughout the experiment
(Figure 1; p,0.0001 for all groups).
Biochemical analysis
The experimental groups had similar TC, Tg, AST, ALT,
ALP, and Cr levels (Table 1). Compared with the control,
the L-name group had increased serum levels of IL-6
(p,0.001) and TNF-a (p,0.01). However, when compared
with the L-name group, treatment with 2 or 20 mg/kg/day
rosuvastatin inhibited the L-NAME-induced increase in the
serum IL-6 (p,0.001 for both groups) and TNF-a levels (L-
name+ROS-20, p=0.030; L-name+ROS-2, p=0.028). The L-
name group showed a significant reduction in the NO level
compared with the control group (p=0.01). Only the
L-name+ROS-2 group showed significantly higher levels
of NO compared with the L-name group (p=0.047; Table 2).
The L-name group showed an increase in the urinary
albumin5creatinine ratio compared with the CTRL group
(p=0.023). Rosuvastatin at both tested doses (2 and 20 mg/
kg/day) lowered the urinary albumin5creatinine ratio
compared with the L-name group (p=0.008 and p=0.047,
respectively) (Figure 2).
Histological analysis
Histological evaluation following staining with hematox-
ylin/eosin (Figure 3 A,D,G,F) or Masson’s trichrome
(Figure 3 B,E,H,K) revealed no detectable renal pathology
in any of the groups in all of the renal compartments. The
cross-sectional glomerular areas were similar among all of
the experimental groups (Table 3).
Immunohistochemical analysis
The L-name group demonstrated an increased number
of macrophages in the renal glomeruli compared with
the CTRL group (p,0.0001). The L-name+ROS-20 and
L-name+ROS-2 groups demonstrated decreased infiltration
of macrophages into the glomeruli compared with the
L-name group (p,0.0001) (Figure 3 C,F,I,L and Table 3).
Table 1 - Biochemical parameters of the experimental groups at the end of the experiment.
Parameter CTRL L-name L-name+ROS-20 L-name+ROS-2
n 10 10 10 10
Serum creatinine, mg/dl 1.1¡0.04 0.9¡0.03 1.0¡0.09 1.0¡0.07
Total cholesterol, mg/dl 71.0¡6.3 74.1¡4.4 82.5¡7.0 72.8¡3.9
Triglycerides, mg/dl 73.8¡5.8 89.2¡6.8 78.7¡15.7 72.6¡4.5
Alanine aminotransferase, U/l 250.3¡45.1 222.4¡7.8 227.3¡13.1 186.1¡13.2
Aspartate aminotransferase, U/l 102.3¡12.1 112.5¡3.5 116.0¡4.0 99.2¡2.4
Alkaline phosphatase, U/l 236.0¡14.6 254.2¡10.2 259.9¡23.5 236.7¡15.3
Data are expressed as the mean ¡ SEM. All groups had similar biochemical parameters when compared with the CTRL group.
Table 2 - Inflammatory parameters of the experimental
groups at the end of the experiment.
Group IL-6 (pg/mL) TNF-a (pg/mL) NO (mM)
CTRL 7.4¡0.4* 25.5¡1.8# 2.1¡0.5#
L-name 25.3¡2.0 35.3¡4.7 0.5¡0.1
L-name+ROS-20 8.7¡0.1* 26.1¡1.4+ 0.8¡0.1
L-name+ROS-2 10.2¡0.5* 25.4¡1.2+ 2.3¡0.6#
The results are expressed as the mean ¡ SEM. n=10 rats/group.
*p,0.001;
#p,0.01;
+p,0.05 when compared with the L-name group.
NO: serum nitric oxide level; IL-6: interleukin-6; TNF-a: tumor necrosis
factor-alpha.
Figure 2 - Urinary albumin5creatinine ratio in experimental
groups. #p,0.05, *p,0.01 when compared with the L-name
group.
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Chronic nitric oxide synthesis inhibition induced by the
treatment of rats with L-NAME results in endothelial
dysfunction, vascular hypertrophy, cardiac fibrosis, athero-
sclerosis, perivascular inflammation, renal failure, and
increased vascular responses to adrenergic stimuli. Several
other factors, including Renin-angiotensin system, endothe-
lial constrictor factors, arterial remodeling and the sympa-
thetic nervous system are involved in these effects.
19,28
Additionally, this experimental model is characterized by
easy handling and low animal mortality.
The dose of 30 mg/kg/day of L-NAME was sufficient to
induce arterial hypertension,
29 and the dose of 20 mg/kg/
day of rosuvastatin used in our study is known to have
beneficial effects on endothelial dysfunction and systemic
and regional hemodynamics.
23 At 2 mg/kg/day, rosuvas-
tatin has been shown to significantly increase eNOS mRNA
and protein expression and decrease iNOS mRNA and
protein expression and nitrite production after ischemia
reperfusion.
30
The L-name group developed hypertension after the end
of the first induction week. At the end of the experiment,
there was a decrease in the serum NO level and an increase
in inflammatory parameters (the serum IL-6 and TNF-a
levels), macrophage infiltration into the glomeruli and
proteinuria.
The effects of statins on blood pressure can be dose
dependent in some animal models, such as spontaneously
hypertensive
31 and angiotensin II–dependent rats.
32 Our
results did not demonstrate a dose-dependent reduction in
blood pressure following treatment with rosuvastatin (2 or
20 mg/kg/day). A similar finding was reported by Susic
et al.
23
In rats, serum lipid levels are usually low, and statins do
not change this profile. Therefore, rats are an excellent
model to study the pleiotropic effects of statins.
23 In our
study, treatment with rosuvastatin did not alter the serum
Tg, TC, ALT, AST, ALP, or Cr levels, which indicates that
rosuvastatin exerted lipid lowering–independent effects.
Furthermore, in our study, the serum ALT, AST, and ALP
levels indicated no liver toxicity.
Biochemical markers, particularly markers of vascular
inflammation, such as high-sensitivity C-reactive protein
(hs-CRP), have been suggested to be predictive of cardio-
vascular events.
33 The primary proinflammatory cytokines
TNF-a and IL-6 are the main inducers of hs-CRP.
Furthermore, according to Navarro and Mora-Fernandez,
34
TNF-a and IL-6 have been associated with significant direct
renal effects.
Figure 3 - Histological and immunohistochemical analysis. Representative glomerular sections stained with hematoxylin/eosin (A,D,G,J;
4006), cortical sections stained with Masson’s trichrome (B,E,H,K; 206) and immunohistochemical analyses of glomerular macrophages
(C,F,I,L) in each group of rats (n=10/group). These analyses did not detect changes in the glomerular, vascular, tubular or interstitial
compartments. Glomerular macrophages were most abundant in the L-name group (arrow).
Table 3 - Glomerular macrophage infiltration and the
cross-sectional glomerular area of the kidneys of animals
at the end of the experiment.
Group
Glomerular macrophage
(%)
Cross-sectional glomerular area
(mm
2)
CTRL 39¡3* 3833¡61
L-name 107¡4 3673¡64
L-name+
ROS-20
56¡4* 3688¡83
L-name+
ROS-2
45¡6* 3911¡75
The results are expressed as the mean ¡ SEM. n=10 rats/group. The
number of macrophages was analyzed in 100 random glomeruli per
animal. The glomerular surface area was morphometrically analyzed in at
least 50 glomeruli per animal.
*p,0.0001 when compared with the L-name group.
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1460In this study, treatment with rosuvastatin (2 or 20 mg/
kg/day) reduced the serum IL-6 and TNF-a levels.
Experimental and clinical studies have demonstrated the
pathogenic role of TNF-a in the development of renal injury
and the potential benefit of modulating TNF-a activity as a
therapeutic target in diverse renal diseases.
35
IL-6 has been correlated with an increased width of the
glomerular basement membrane.
35 It also enhances fibro-
nectin expression, affects extracellular matrix dynamics at
both the mesangial and podocyte levels, stimulates mesan-
gial cell proliferation, and increases endothelial permeabil-
ity.
36,37 IL-6 plays an important role in vascular remodeling
and has been reported to be a useful biomarker in predicting
future cardiovascular events.
38
TNF-a is cytotoxic to glomerular, mesangial and
epithelial cells, and it is able to induce direct renal
damage.
39 Furthermore, TNF-a stimulates endothelial
generation of reactive oxygen species by activating the
NADPH oxidase subunits gp91 phox, NOX-1, p47phox,
and p22phox. TNF-a also activates the transcription of
NF-kB, which regulates the expression of genes in-
volved in inflammation, oxidative stress and endothelial
dysfunction.
11,38
Animals treated simultaneously with L-NAME and
rosuvastatin (2 mg/kg/day; L-name+ROS-2) had an
increased serum NO level and reduced L-NAME-induced
inflammatory parameters. However, treatment with 20 mg/
kg/day rosuvastatin (L-name+ROS-20) did not alter the
serum NO levels compared with the L-name group. This
finding could be because a lower dose (2 mg/kg/day) of
rosuvastatin may increase the constitutive endothelial
bioavailability of NO, which may not occur at higher doses
(20 mg/kg/day). Di Napoli et al.
30 evaluated the effects of
rosuvastatin on reperfusion injury in rat hearts using 0.2, 2,
and 20 mg/kg/day rosuvastatin. They found that 2 mg/
kg/day rosuvastatin significantly increased the mRNA
expression of constitutive endothelial NOS (eNOS) com-
pared with the untreated group and reduced the mRNA
expression of inducible NOS (iNOS). These effects were
more evident at 2 mg/kg/day rosuvastatin than at 0.2 mg/
kg/day rosuvastatin. However, at the highest dosage
(20 mg/kg/day) there was a beneficial effects loss in the
expression of eNOS and iNOS associated with increased
mitochondrial damage and microcirculatory dysfunction.
The current treatment of chronic nephropathy is limited
to angiotensin-converting enzyme inhibitors and angioten-
sin AT1 receptor blockers; however, evidence indicates that
statins can be effective.
11
Glomerulosclerosis, glomerular ischemia, and interstitial
fibrosis were observed in the kidneys of nitric oxide–
deficient rats fed a high-salt diet.
40 Changes in glomerular
and vascular densities were also observed in this model
using stereological analysis.
41 The BPs achieved in the
animals used in these previous studies were 212 and
200–225 mmHg, respectively. However, Lecian et al.
42
found no histological abnormalities in the kidneys of rats
treated with a nitric oxide synthesis inhibitor, and these
animals had a BP of 175 mmHg. In our study, the BP of the
hypertensive group only reached 140 mmHg, which may
explain the absence of histological abnormalities.
Statins inhibit several intracellular signaling pathways
(Rho/RhoA and MAPK pathways) activated by angiotensin
II that are involved in the regulation of profibrotic factors,
connective tissue growth factor and the deposition of
extracellular matrix components, which are all modulated
by redox processes.
43 Our data demonstrate that there was a
significant increase in the accumulation of macrophages in
the glomeruli and proteinuria in L-NAME-treated rats.
Rosuvastatin was effective in reducing glomerular macro-
phage infiltration, which is indicative of an improved
inflammatory pattern; however, this effect was most evident
at a dose of 2 mg/kg/day. Additionally, rosuvastatin
inhibited proteinuria at both of the tested doses (2 or
20 mg/kg/day).
CONCLUSIONS
In conclusion, rosuvastatin reduces the serum levels of IL-
6 and TNF-a, reduces glomerular macrophage infiltration
and prevents proteinuria in this experimental model. All of
the effects of rosuvastatin were independent of its lipid-
lowering effects. Future mechanistic studies will examine
the molecular mechanisms involved in these effects. Our
data suggest that rosuvastatin may act beneficially in
preventing proteinuria and glomerular inflammation in a
model of nitric oxide deficiency.
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